Oral combination of HMAs + venetoclax in unfit or elderly patients with AML

Daniel Pollyea | ASH 2018 | Venetoclax plus HMAs in patients with AML unfit for intensive therapyПодробнее

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AMLПодробнее

Venetoclax for elderly AML patientsПодробнее

Novel approaches to treating AML in elderly patientsПодробнее

Venetoclax + azacitidine in unfit patients with AMLПодробнее

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

Venetoclax, CLAD/LDAC and azacitdine in older AML patientsПодробнее

Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AMLПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapyПодробнее

Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2Подробнее

What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?Подробнее

HMA in combination with venetoclax and magrolimab in the treatment of AMLПодробнее

Venetoclax Combination Therapy and Elderly AML PatientsПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AMLПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее

Oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with AMLПодробнее

Current research in elderly, untreated AML: venetoclax combinationsПодробнее